Envoy Medical Reports 34.6% Revenue Decline in Q2 2026, Operating Loss Increases

Envoy Medical, Inc. reported its financial results for the second quarter of 2026, revealing a net revenue of $51,000, a decrease of 34.6% compared to $78,000 in the same period last year. For the first half of 2026, the company generated $90,000 in revenue, down 27.4% from $124,000 in the first half of 2025. The company continues to face challenges in revenue generation, primarily due to limited sales of its Esteem Fully Implanted Active Middle Ear Implant, which has not gained significant market traction.

The company's operating loss for the second quarter of 2026 was $5.6 million, compared to a loss of $5.1 million in the same quarter of 2025. For the six months ended June 30, 2026, the operating loss increased to $11.5 million from $10.2 million in the prior year. The increase in operating expenses was driven by a 26% rise in research and development costs, which totaled $3.1 million for the quarter, reflecting ongoing clinical trials for the Acclaim Cochlear Implant, the company’s investigational product. General and administrative expenses remained relatively stable, while sales and marketing expenses decreased significantly due to a reallocation of resources.

Envoy Medical has made strategic advancements, particularly in its clinical development efforts for the Acclaim Cochlear Implant, which received Breakthrough Device Designation from the FDA in 2019. The company completed enrollment of 56 patients in its pivotal clinical trial by March 2026, with all participants surpassing the three-month milestone by July 2026. The company plans to submit a Premarket Approval (PMA) application to the FDA in the second half of 2027, contingent on the successful completion of the clinical trial.

As of June 30, 2026, Envoy Medical reported total assets of $23.9 million, a significant increase from $8.6 million at the end of 2025, primarily due to cash raised from recent equity offerings. The company had cash reserves of $19.7 million, up from $3.7 million at the end of the previous year. However, the company continues to face substantial doubt about its ability to continue as a going concern, as it has accumulated losses of $326.4 million and expects to incur further losses as it advances its clinical programs and seeks regulatory approvals.

Looking ahead, Envoy Medical anticipates continued increases in research and development expenses as it progresses with the Acclaim CI clinical trials. The company is also exploring additional financing options to support its operations, including potential proceeds from the exercise of outstanding warrants. However, there are no guarantees regarding the timing or success of these efforts, and the company may need to reduce discretionary spending if it cannot secure sufficient funding.